Open AccessP1272: GP130/STAT3 AXIS IS A POTENTIAL THERAPEUTIC TARGET FOR HISTONE DEACETYLASE INHIBITOR‐RESISTANT CUTANEOUS T‐CELL LYMPHOMA
Author(s) -
Takahashi Y.,
Kitadate A.,
Ikeda S.,
Iwama S.,
Abe K.,
Matsuda Y.,
Tagawa H.,
Wakui H.,
Takahashi N.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847952.99146.35
Subject(s) - vorinostat , romidepsin , cancer research , histone deacetylase , histone deacetylase inhibitor , ibrutinib , lymphoma , cell culture , biology , leukemia , immunology , chronic lymphocytic leukemia , histone , gene , biochemistry , genetics